SPY417.26+1.39 0.33%
DIA341.86+1.53 0.45%
IXIC14,052.34+13.58 0.10%

Shattuck Labs: Initial Dose-Escalation Data From Phase 1 Clinical Trial for Lead Wholly Owned CD47 Checkpoint Inhibitor, SL-172154, Expected in 2H >STTK

Shattuck Labs: Initial Dose-Escalation Data From Phase 1 Clinical Trial for Lead Wholly Owned CD47 Checkpoint Inhibitor, SL-172154, Expected in 2H >STTK

· 03/15/2021 16:48

Please log in to view news